1Bauer KR, Brown M, Cress RD, al. Descriptive analy-sis of estrogen receptor (ER) -negative, progesterone re-ceptor (PR)-negative, and HER2-negative invasive breastcancer, the so-called triple-negative phenotype: a popula-tion-based study from the California cancer Registry [J].Cancer,2007,109(9) :1 721.
2Jones S,Holmes FA,O'Shaughnessy J,et al. Docetaxelwith cyclophosphamide is associated with an overall sur-vival benefit compared with doxorubicin and cyclophospha-mide: 7-year follow-up of us oncology research trial 9 735[J]. J Clin Oncol, 2009,27(8):1 177.
3Ghersi D,Willson ML,Chan MM,et al.Taxane-containingregimens for metastatic breast cancer[J]. Cochrane Data-base Syst Rev ,2015(6) ;CD 003 366.
4Rivera E,Mejia JA,Arun BK,et al. Phase 3 study compar-ing the use of docetaxel on an every-3-week versus week-ly schedule in the treatment of metastatic breast cancer[J].Ca.cer,2008,112(7):l 455.
5Lluch A,Alvarez I,Munoz M,et al. Treatment innovationsfor metastatic breast cancer: nanoparticle albumin-bound(NAB) technology targeted to tumorsfJ]. Crit Rev Oncol/fem(加/,2014,89(1) :62.
6Palumbo R,Sottotetti F,Trifiro G,et al. Nanoparticle albu-min-bound paclitaxel (nab-paclitaxel) as second-line che-motherapy in HER2-negative,taxane-pretreated metastat-ic breast cancer patients : prospective evaluation of activi-ty, safety, and quality of life[J]. Drug Des Devel Ther,2015,9(2):189.
7Fan Y, Xu BH,Yuan P,et al. Docetaxel-cisplatin might besuperior to docetaxel-capecitabine in the first-line treat-ment of metastatic triple-negative breast cancer[J]. AnnOnco/,2013,24(5):1 219.
8Staudacher L,Cottu PH,Dieras V,et al.Platinum-based ch-emotherapy in metastatic triple-negative breast cancer:the Institut Curie experience[J]. Ann Oncol,2011,22(4):848.
9IsakofF SJ,Mayer EL,He L,e/ aL TBCRC009 : a multice-nter phase II clinical trial of platinum monotherapy withbiomarker assessment in metastatic triple-negative breastcancer[J]. J Clin2015,33(17) : 1 902.
10Zhang J, Wang Z, Hu X, et al. Cisplatin and gemcitabineas the first line therapy in metastatic triple negative breastcancer[ J]. Int J Cancer ,2015,136(1): 204.
